Codeine

psilodex.org/m/codeine · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: ~3 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: codeine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Opioid; sedation, nausea and respiratory depression add to psilocybin's nausea and to any other sedatives. Converted to morphine by CYP2D6, so exposure varies with genotype. Abrupt stopping after regular use can cause serious withdrawal.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: ~3 h (codeine and metabolites) (FDA label, checked 2026-10-02)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Chronic painCO 2.5(A)(2)

05 Sources

Codeine Sulfate Tablet · FDA label (DailyMed) — Boxed warning on CNS depressants; 2.5/5.16 abrupt discontinuation; CYP2D6 variability

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →